Introduction

The process of the SARS-CoV-2 spike protein entering human cells.

SARS-CoV-2 better known as Covid-19 sent the world into a global pandemic due to its rapid transmission and infection ^[1]. In order to create a vaccine, it was essential to understand how SARS-CoV-2 infected us.

The enzyme angiotensin converting enzyme 2 is attached to our cell membranes and then can be bound to a receptor binding domain (RBD) ^[2]. The spike protein of SARS-CoV-2 enters our bodies and binds to the RBD, allowing the spike protein access to ACE2 and our host cells ^[3]. Once the spike protein has access to our host cells, it is able to further infect our cells and spread the virus throughout our bodies, causing us to get sick. In order to create an effective vaccine, the pathway between the spike protein and the RBD needed to be interrupted.

Vaccines

A common way to create vaccines is through the usage of antibodies. are inserted into the body that mimic ACE2, due to the similarities with ACE2, when COVID-19 spike protein enters the body, they to these ACE2 mimicking antibodies that create a 90% neutralizing response for targeting the RBD. With this being said, this method of treatment is difficult for long term use due to the evolution of the viral cells ^[4].

AHB2 and LCB1/LCB3 Specifically

Protein inhibitors were thought of as a new idea for creating vaccines due to their smaller size and better stability compared to antibody vaccines^[5]. These protein inhibitors are also referred to as mini-binders, they interact with the ACE2 receptor binding domain,

Their Discovery

The use of the Rosetta Blueprint protein design to create the AHB2 inhibitor.

The first mini-binder to be created to combat COVID-19 is called AHB2. In order to ensure that the mini-binder would bind to the same RBD that the ACE2 was bound to, AHB2 was designed by looking at sequence of ACE2 alpha-helix that makes interactions with spike receptor binding domain. This design process is referred to as the Rosetta Blueprint protein design ^[5].

The use of the De Novo protein design to create the LCB1 and LCB3 inhibitors.

As the AHB2 inhibitors were tested and found to be effective, it was then time to manipulate the mini-binders to create a more effective vaccine. A rotamer interaction field docking with in silico mini-proteins were used by using a scaffold library to generate binders to more distinct regions of the RBD surface ^[5]. This method is known as the de novo protein design and it is how the LCB1 and LCB3 mini-binders were created.

Binding Site and Interactions

In order to best target the RBD of the spike protein, the minibinders reveal a wide range of interactions to compete with . ACE2's main interactions with the spike protein include D30, H34, Y41, D38, and E35 of ACE2 with K417, Y453, Q498, K353, and Q493 of the spike protein, respectively.

The first design method, Rosetta blueprint, created AHB2 based on the single interacting helix of ACE2. With , we see two alpha helices mimicking ACE2. Hydrogen bonding interactions between N36, D11, K43, E41, and E30 of the minibinder interact with residues K417, R403, Y449, Q493, and N487, respectively, in the spike protein. One interesting result of the Rosetta blueprint design was the addition of the second helix to interact with the spike protein. It is assumed that this addition further stabilizes the interaction, increasing stability of the minibinder:spike complex.

De novo designed proteins, as discussed previously, focused on computational design to determine residues best able to interact with the spike protein. We will focus on LCB1 and LCB3. reveals hydrogen bonding between D30 of the minibinder and both K417 and R403 of the spike protein, in addition to D17 and R14 of the minibinder interacting with Q493 of the spike protein. Similarly, reveals hydrogen bonding between D11 of the minibinder to K417 and R403 of the spike protein.

Within all four binding sites, we see two spike protein residues interacting with all four minibinders: K417 and Q493. This suggests that these resides are critical for binding.

Furthermore, an interesting difference between the two methodologies is revealed in the locations of hydrogen bonding. In the de novo designed minibinders, we see the main interactions occurring in the center of the RBD, whereas ACE2 and AHB2 reveal hydrogen bonding interactions throughout the length of the helices. Shown below is a sequence alignment between ACE2 and the three minibinders.

The sequence differences between ACE2, AHB2, LCB1, and LCB3.

Stability

One of the most important findings with these DeNovo proteins is their high stability, allowing for less delicate forms of administration. , , and